Participated · Seed · Sep 2025

Founded in 2022 by the serial cybersecurity entrepreneurs behind Demisto, Los Altos-based Descope offers a visual, drag-and-drop external IAM platform that lets developers create, modify, and manage authentication and authorization journeys for end users, partners, AI agents, and MCP servers. The product includes capabilities such as a connectors ecosystem, identity federation broker, agentic identity hub, and FedRAMP High-authorized offerings, all delivered with a developer-friendly no-code/low-code interface. Descope’s platform is now used by over a thousand organizations in production, serving thousands of companies overall, saving time for tens of thousands of developers, and managing hundreds of millions of identities. The company has earned recognition from KuppingerCole, Frost & Sullivan, Gartner, Fortune’s Cyber 60, and others. With total seed funding of $88 million, Descope is well-capitalized to pursue its roadmap. The newly raised capital will fund further R&D in agentic identity, geographic expansion, and headcount growth across engineering, product, and customer experience teams.

Participated · Equity · Nov 2024

TailorMed provides an enterprise platform that manages the full lifecycle of patient support programs to reduce cost barriers and improve medication access and adherence. The company has built the nation’s largest Affordability Network, deployed across more than 800 hospitals, 1,300 clinics, and 650 pharmacies. TailorMed integrates directly with manufacturer assistance programs to automate patient support and streamline stakeholder workflows. Having reached an inflection point in its network evolution, the company is expanding into an end-to-end platform to tackle cost, access, and adherence across the medication continuum. The new financing will fund that expansion and broader efforts to create a seamless flow of data and resources across patients, providers, pharmacies, life sciences, and payers. TailorMed frames this work as addressing affordability at the point a prescription is written or dispensed to prevent delayed or skipped treatments. TailorMed Medical provides a technology platform that automates identification of financially at-risk patients and matches and enrolls them in financial resources such as co-pay assistance, replacement drug programs, government subsidies, community and state resources, disease-specific foundations, and programs addressing living expenses. Its platform is designed to reduce out-of-pocket responsibility for patients, helping to eliminate downstream financial hardship and avoidance of care. For health organizations, TailorMed shifts financial assistance from reactive matching or downstream collections to a proactive, point-of-care approach. The company serves physician practices, specialty clinics and health systems, and in 2021 expanded adoption into pharmacies nationwide. TailorMed said it will use the new funding to further expand its reach across health care with innovative financial solutions. Srulik Dvorsky is CEO and co-founder and the company is based in New York City.

Led · Equity · Oct 2024

FeelBetter has developed an AI-based Pharmaco-Clinical Intelligence platform with four core tools: Insight (risk stratification), Navigator (workflow management), Action (AI decision-support for pharmacists) and Impact (post-intervention monitoring). The company reports reaching more than 300,000 patients daily and cites partnerships with Leumit HMO, Atlantic Health, and a retrospective study at Brigham & Women’s Hospital validating its outcomes. Published and partner-reported results include large reductions in hospital admissions and days, clinical improvements in LDL and HbA1c, a 5x increase in pharmacist capacity reported by Leumit, and estimated cost savings per high-risk patient. FeelBetter has raised $11.5 million from grants and investors to date and is actively seeking Series A funding. The firm says it is expanding its global footprint and plans to partner with more U.S.-based health systems to pursue broader adoption of its population- and individual-level solution.

Participated · Series A · Oct 2024

Monogoto offers a software-defined connectivity platform that centralizes management of cellular, private LTE/5G and satellite connections for devices and fleets. The platform spans 180 countries and 550 networks and supports both SIM-based and software connectivity solutions. Customers include businesses in asset tracking, smart metering, fleet management and telematics, point-of-sale, retail, healthcare, and micromobility. The company was co-founded by CEO Itamar Kunik and CTO Maor Efrati; Kunik previously worked on telecom infrastructure projects with Israel’s 8200 unit. Monogoto is positioned as a developer-friendly API-style alternative for provisioning connectivity at scale. Financially, the company disclosed a $27M Series A and has raised $38M in total to date; valuation was not disclosed. Monogoto offers a global, cloud-based cellular connectivity platform and APIs that enable enterprises and developers to design, build, manage, control and scale IoT and M2M applications. Its platform connects and controls cellular-based sensors and devices across use cases such as point-of-sale terminals, ATMs, wearables, smart lighting, fleets and package tracking. The company serves more than 100 customers worldwide, including Sodaq, Connected You, Origin GPS and Tvilight. Monogoto intends to use new funding to expand its U.S. presence with a San Francisco office, grow product sales, and boost brand awareness and market penetration. It also plans to enrich B2D assets with additional APIs, documentation and developer tools, extend its global points of presence, and expedite and strengthen its network’s 5G infrastructure. The company is led by CEO Itamar Kunik.

Participated · Series C · Mar 2024

Brightside Health is a telemental health provider that combines proprietary AI, purpose-built technology, and a clinician network to deliver precision psychiatry, therapy, and an award-winning Crisis Care program for individuals with elevated suicide risk. Its services are available to commercially insured and cash-pay patients in all 50 states and D.C., with appointments available in 48 hours or less, and to Medicaid and Medicare beneficiaries in select states. The company has expanded payer partnerships, including CareOregon, Blue Cross and Blue Shield of Texas, and Centene, and has published close to a dozen peer-reviewed research papers. Leadership has focused on building programs for individuals with severe mental health conditions and expanding into underserved markets. Brightside reports a capital-efficient approach and says the organization is on a comfortable path to profitability. The recent strategic Series C will support growth into new markets and new offerings and deeper Medicare and Medicaid expansion. Brightside Health is a telemedicine platform offering fast access to personalized mental health treatment, expert providers, and ongoing support via video visits, unlimited messaging, and medication delivery. The company pairs clinicians with data and technology, using a proprietary machine-learning algorithm that evaluates more than 100 data points to help providers tailor treatment and enable precision psychiatry. Its care model follows evidence-based, structured protocols delivered by a network of psychiatric providers and licensed therapists, with online check-ins monitored by providers to ensure efficacy. Brightside reports that 86% of members feel better within the first 12 weeks and 71% achieve remission in that period; a recent study showed over 50% higher treatment response and remission rates than a leading U.S. health system. The company plans to use new capital to grow headcount from 57 to an expected 175 employees this year, further enhance its platform and partnerships, and expand access to more individuals. Brightside already has go-to-market partnerships with clinically-discerning national payers that open access to superior mental health care for over 30 million insurance members nationwide.